Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.32 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.32 |
| ▸ | NMT2 | O60551 | 1/20 | 0.32 |
| ▸ | NMT1 | P30419 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.31 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.31 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.31 |
| ▸ | FURIN | P09958 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24239548 | 1.00 | OPRK1 (0.33) | OPRK1ITGB3ITGA2BNMT2NMT1 | |
| SCHEMBL21902132 | 0.94 | OPRK1 (0.31) | OPRK1ITGB3ITGA2B | |
| SCHEMBL24220950 | 0.94 | NMT2 (0.32) | ITGB3ITGA2BNMT2NMT1 | |
| SCHEMBL18929779 | 0.92 | OPRK1 (0.30) | OPRK1 | |
| SCHEMBL11956479 | 0.89 | KDM4E (0.35) | ITGB3ITGA2BKDM4EALDH1A1 | |
| SCHEMBL16248631 | 0.89 | KDM4E (0.35) | ITGB3ITGA2BKDM4EALDH1A1 | |
| SCHEMBL17662433 | 0.89 | KDM4E (0.35) | ITGB3ITGA2BKDM4EALDH1A1 | |
| SCHEMBL20016488 | 0.88 | OPRK1 (0.33) | OPRK1ITGB3ITGA2BNMT2NMT1 | |
| SCHEMBL24703967 | 0.88 | NMT1 (0.38) | NMT2NMT1SIRT6SIRT1FURIN | |
| SCHEMBL23191800 | 0.88 | NMT1 (0.38) | NMT2NMT1SIRT6SIRT1FURIN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11312964-B2 | Compositions and methods for modulating growth hormone receptor expression | IONIS PHARMACEUTICALS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-20220031730-A1 | ENHANCED OLIGONUCLEOTIDES FOR MODULATING FUBP1 EXPRESSION | HOFFMANN-LA ROCHE INC. (US) | 2022-02-03 | — | — | US | disclosed |
| US-20210395734-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2021-12-23 | — | — | US | disclosed |
| US-20210207146-A1 | COMPOSITIONS AND METHODS FOR MODULATING GROWTH HORMONE RECEPTOR EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2021-07-08 | — | — | US | disclosed |
| US-20210087566-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN (a) EXPRESSION | IONIS PHARMACEUTICALS, INC. | 2021-03-25 | — | — | US | disclosed |
| US-20200224198-A1 | COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2020-07-16 | — | — | US | disclosed |
| US-10683499-B2 | Compositions and methods for modulating TTR expression | IONIS PHARMACEUTICALS, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-10294477-B2 | Compositions and methods for modulating PKK expression | IONIS PHARMACEUTICALS, INC. (US) | 2019-05-21 | — | — | US | disclosed |
| US-20190127737-A1 | SINGLE-STRANDED RNAI OLIGONUCLEOTIDES TARGETING APOC-III | IONIS PHARMACEUTICALS, INC. (US) | 2019-05-02 | — | — | US | disclosed |
| US-20180044676-A1 | COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2018-02-15 | — | — | US | disclosed |
| US-20170183661-A1 | COMPOSITIONS AND METHODS FOR MODULATING PKK EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2017-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220031730-A1 | ENHANCED OLIGONUCLEOTIDES FOR MODULATING FUBP1 EXPRESSION | FUBP1, FUBP3, IGF2BP1 | OPRK1 4164/4885ITGB3 3188/4885ITGA2B 2935/4885 |
| US-20180044676-A1 | COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION | TTR, GALNT1, GALNT3 | OPRK1 2905/4885ITGB3 352/4885ITGA2B 303/4885 |
| US-20210087566-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN (a) EXPRESSION | APOB, APOL1, LDLR | OPRK1 1187/4885ITGB3 816/4885ITGA2B 396/4885 |
| US-20200224198-A1 | COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION | HAVCR2, HCCS, HDGF | OPRK1 2529/4885ITGB3 560/4885ITGA2B 439/4885 |
| US-10683499-B2 | Compositions and methods for modulating TTR expression | TTR, GALNT1, GALNT3 | OPRK1 2905/4885ITGB3 352/4885ITGA2B 303/4885 |
| US-20210395734-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION | APOB, APOL1, LDLR | OPRK1 1155/4885ITGB3 66/4885ITGA2B 355/4885 |
| US-10294477-B2 | Compositions and methods for modulating PKK expression | GCKR, PKM, PKLR | OPRK1 444/4885ITGB3 2390/4885ITGA2B 2582/4885 |
| US-20190127737-A1 | SINGLE-STRANDED RNAI OLIGONUCLEOTIDES TARGETING APOC-III | APOB, APOL1, RBM3 | OPRK1 2601/4885ITGB3 645/4885ITGA2B 1105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.